CollPlant Biotechnologies Ltd

CLGN Nasdaq SEC CIK 1631487
Follow CollPlant Biotechnologies Weekly email: filings, results, news

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
EPS, diluted -
Revenue by quarter
$249K
$179K
Q2 24 Q2 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$20M−$10M$0$10M$20MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$2.4M−$11.5M
FY24$515K−$16.6M
FY23$11M−$7M
FY22$299K−$16.9M
FY21$15.6M$237K
FY20$6.1M−$5.8M
FY19$2.3M−$11.2M
FY18$5M−$6.2M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%2000%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2564.8%−484.3%−484.6%
FY24−215.5%−3349.7%−3225%
FY2381.8%−68.5%−64%
FY22−33.8%−5718.1%−5660.5%
FY2187.2%0.4%1.5%
FY2051.1%−91.2%−94.1%
FY1918.9%−329.2%−481.6%
FY1866.9%−84.7%−124.6%
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0$5MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$9.4M
FY24−$14.6M
FY23−$3.7M
FY22−$15M
FY21$1.1M
FY20−$4.9M
FY19−$7.2M
FY18−$2M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • CollPlant Biotechnologies
  • Healthcare median
−6000%−4000%−2000%0%2000%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearCollPlant BiotechnologiesHealthcare median
FY25−484.6%−40.6%
FY24−3225%−60.7%
FY23−64%−97.1%
FY22−5660.5%−128.5%
FY211.5%−129.2%
FY20−94.1%−136.5%
FY19−481.6%−133.7%
FY18−124.6%−173.4%
FY17-−176.7%

News

No stories filed under CollPlant Biotechnologies yet - coverage appears here as the news feed clusters it.